Zoledronic acid: An unending tale for an antiresorptive agent

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 1, 2010, Pages 141-154

  Caraglia, Michele ^a   Marra, Monica ^a   Naviglio, Silvio ^a   Botti, Gerardo ^b   Addeo, Raffaele ^c   Abbruzzese, Alberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

Anticancer; Breast cancer; Cyr61; Cytotoxic drugs; Metronomic; Pharmacokinetic; Prostate cancer; Tipifarnib; Zoledronic acid

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; DOXYCYCLINE; ESTRAMUSTINE; EVEROLIMUS; GEFITINIB; IBANDRONIC ACID; IMATINIB; NANOPARTICLE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SORAFENIB; TAMOXIFEN; TIPIFARNIB; UFT; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER TISSUE; CELL DEATH; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; JAW OSTEONECROSIS; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; HYDROXIDES; IMIDAZOLES; MALE; OXIDES; PROSTATIC NEOPLASMS; PROTEIN PRENYLATION;

EID: 72849106099     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903485664     Document Type: Review

References (93)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34
2. Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97:840-847 .
3. Soma MR, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 1992:64-65
4. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658
5. Rogers MJ. From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75:451-461
6. Reid TS, Terry KL, Casey PJ, et al. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004;343:417-433
7. Simonen M, Ibig-Rehm Y, Hofmann G, et al. High-content assay to study protein prenylation. J Biomol Screen 2008;13:456-467
8. Santini D, Caraglia M, Vincenzi B, et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006;3:325-338 .
9. Green JR. Bisphosphonates: Preclinical review. Oncologist 2004;9(Suppl 4):S3-13
10. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882 . (Pubitemid 38807610)
11. Lipton A, Seaman J, Zheng M. Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. In: What is new in bisphosphonates? seventh workshop on bisphosphonates - from the laboratory to the patient. Davos, Switzerland, 24 - 26 March 2004
12. Mönkkönen H, Ottewell PD, Kuokkanen J, et al. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 2007;81:1066-1070
13. Räikkönen J, Crockett JC, Rogers MJ, et al. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009;157:427-435 .
14. Caraglia M, D'Alessandro AM, Marra M, et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004;23:6900-6913 .
15. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;295:295-306
16. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs [Ras] membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-1486
17. Ho LH, Read SH, Dorstyn L, et al. Caspase-2 is required for cell death induced by cytoskeletal disruption. Oncogene 2008;27:3393-3404
18. Sewing L, Steinberg F, Schmidt H, Göke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008;13:782-789
19. Ory B, Blanchard F, Battaglia S, et al. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007;71:333-343
20. Pandha H, Birchall L, Meyer B, et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 2006;176:2255-2261
21. Soltau J, Zirrgiebel U, Esser N, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 2008;28:933-941
22. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954
23. Pickering LM. Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling. Proc Am Soc Clin Oncol 2003;22:3468
24. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061
25. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492
26. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544
27. Bonjean K. Zoledronate modulates endothelial cell surface receptors involved in angiogenesis. Proc Am Assoc Cancer Res 2001;42:576
28. Bellahcène A, Chaplet M, Bonjean K, et al. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium 2007;14:123-130
29. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-151 .
30. Santini D, Vincenzi B, Hannon RA, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumors. Oncol Rep 2006;15:1351-1357
31. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13:4482-4486 .
32. Koto K, Horie N, Kimura S, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 2009;274:271-278
33. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-633 .
34. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005;116:94-99
35. Caccamo N, Meraviglia S, Scarpa F, et al. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: Doubts no more. Expert Opin Biol Ther 2008;8:875-883
36. Takagi K, Takagi M, Kanangat S, et al. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: Regulation by STAT1-dependent pathways. J Immunol 2005;174:1801-1810
37. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-1166
38. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008;57:1451-1459 .
39. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594
40. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176
41. Rosen LS, Gordon DH, DuganWJr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43 .
42. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854
43. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791
44. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744 .
45. Major PP. Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc Am Soc Clin Oncol 2003;22:3062
46. Marra M, Santini D, Tonini G, et al. Molecular and preclinical models enhancing anti-tumor activity of zoledronic acid. Eur J Cancer 2008;6:79-85
47. Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res 2007;26:307-312
48. Diel IJ, Weide R, Köppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: A retrospective medical records review. Support Care Cancer 2009;17:719-725
49. Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: Current issues. J Support Oncol 2007;5:475-482
50. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
51. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-847
52. Jadu F, Lee L, Pharoah M, et al. A retrospective study assessing theincidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-2019
53. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-145 .
54. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-120 .
55. Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 2007;64:198-207
56. Chen T. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236 .
57. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7-26 .
58. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154-162
59. Weiss HM, Pfaar U, Schweitzer A, et al. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008;36:2043-2049
60. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55
61. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69:35-43
62. Caraglia M, Marra M, Leonetti C, et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Phys 2007;211:533-543 .
63. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anti-cancer agents. Cancer Treat Rev 2003;29:407-415
64. Ullén A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-650
65. Morgan C, Lewis PD, Jones RM, et al. The in vitro anti-tumor activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 2007;6:669-677
66. Karabulut B, Erten C, Gul MK, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009;33:239-246
67. Brubaker KD, Brown LG, Vessella RL, et al. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;17:6-15
68. Fabbri F, Brigliadori G, Carloni S, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 2008;8:6-43
69. Vordos D, Paule B, Vacherot F, et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 2004;94:524-527
70. Kattan JG, Farhat FS, Chahine GY, et al. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs 2008;26:75-79
71. Morgan TM, Pitts TE, Gross TS, et al. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008;68:861-871
72. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-3715
73. Lu S, Zhang J, Zhou Z, et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008;20:581-587
74. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003;106:973-979
75. Duivenvoorden WC, Vukmirovic-Popovic S, Kalina M, et al. Effect of zoledronic acid on the doxycycline-induced decrease in tumor burden in a bone metastasis model of human breast cancer. Br J Cancer 2007;96:1526-1531
76. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-4567
77. van Beek ER, Lowik CW, van Wijngaarden J, et al. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Res Treat 2009;118:307-313
78. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-1177 .
79. Ottewell PD, Deux B, Mönkkönen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14:4658-4666
80. Wilhelm M, Kunzmann V, Eckstein S, et al. gammadT cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-206
81. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadT cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7457
82. Todaro M, D'Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182:7287-7296
83. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691 .
84. Marra M, Santini D, Meo G, et al. CYR61 down-modulation potentiates the anti-cancer effects of Zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009;125:2004-2013.
85. Pan B, Farrugia AN, To LB, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-154
86. Viereck V, Emons G, Lauck V, et al. The bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686
87. Harrington KJ, Syrigos KN, Vile RG. Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol 2002;54:1573-1600
88. van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: Perspectives in research and therapeutics. J Liposome Res 2002;12:81-94
89. Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003;108:2798-2804
90. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. J Chemother 2004;16:94-97 .
91. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinetics 2003;42:419-436
92. Caraglia M, Addeo R, Costanzo R, et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumors. Cancer Chemother Pharmacol 2005;12:1-6
93. Simoni D, Gebbia N, Invidiata FP, et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo anti-tumour activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem 2008;51:6800-6807 .